Page data last changed: . Registry refreshes and identity assessments are separate from scientific content review.
A satiety peptide carved out of the larger nucleobindin-2 protein.
Part of the Metabolic & GLP-1 peptides cluster
Overview
Nesfatin-1 is a peptide cleaved from the precursor protein nucleobindin-2 (NUCB2), produced in the hypothalamus and in peripheral tissues. It is studied as a satiety-associated signal in appetite and energy-balance research, and is a frequent topic in metabolic neuropeptide literature.
Source & context
Biological / chemical source: Derived from nucleobindin-2 (NUCB2); expressed in hypothalamus and periphery
Primary research or clinical context: Endogenous peptide studied in appetite and metabolism research
From NUCB2 to nesfatin-1
Nucleobindin-2 is a larger calcium- and DNA-binding protein; proteolytic processing releases nesfatin-1 as its N-terminal fragment. This precursor relationship is why databases index the peptide under the NUCB2 gene, and it illustrates how a single protein can serve both structural and signaling roles.
Research context
Nesfatin-1 is investigated for its associations with appetite regulation, glucose handling and stress responses across brain and peripheral tissues. Much of this work is preclinical, and mechanisms are still being mapped. Coverage here is educational and does not describe any human therapeutic use.
Structure & chemistry
Molecular identity & reference confidence
Reference mass unavailable
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Nesfatin-1 (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
Clinical development snapshot
ClinicalTrials.gov lists 6 registered studies with “Nesfatin-1” as an intervention (snapshot 2026-09-06). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT06254976 | Serum Nesfatin-1 and Human Cartilage Glycoprotein-39 Levels in Knee Osteoarthritis | Not applicable | completed | 2024-02-23 |
| NCT04371133 | Anti-inflammatory Markers in Endometrioma | — | completed | 2020-05-01 |
| NCT04298515 | Nesfatin-1 Level in Patients With Type 2 Diabetes, Insulin Resistance and Obesity | Not applicable | unknown | 2020-03-06 |
| NCT03870035 | Role of Nesfatin-1 and Nicotinamide in Infertile Women With Polycystic Ovary Syndrome | — | unknown | 2019-04-26 |
| NCT03808571 | Cord Blood Nesfatin-1 and Irisin in the Intrauterine Growth Restricted Fetuses | — | completed | 2019-01-22 |
| NCT02683954 | The Association Between Endometriosis, Obesity and nesfatin1 | — | completed | 2016-04-04 |
FAQ about Nesfatin-1
What is Nesfatin-1?+
Nesfatin-1 is a peptide cleaved from the precursor protein nucleobindin-2 (NUCB2), produced in the hypothalamus and in peripheral tissues. It is studied as a satiety-associated signal in appetite and energy-balance research, and is a frequent topic in metabolic neuropeptide literature.
What Canadian product status is recorded for Nesfatin-1?+
Canadian product status for Nesfatin-1 has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Nesfatin-1?+
Nesfatin-1 is commonly described as approximately 82 amino acids (Neuropeptide / metabolic peptide).
Related peptides
References & further reading
- 1.Taché et al. (2013). New developments on NUCB2/nesfatin-1. Curr Pharm Des
- 2.Mohan et al. (2013). Phylogenetic aspects of nucleobindin-2/nesfatin-1. Curr Pharm Des
- 3.Ahn et al. (2023). Nesfatin-1 regulates steroidogenesis in mouse Leydig cells. Peptides
- 4.Gu et al. (2022). NUCB2/Nesfatin-1 Regulation of Chronic Visceral Hyperalgesia. Appl Bionics Biomech
- 5.Zhou et al. (2024). Nesfatin-1: A Biomarker and Potential Therapeutic Target in Neurological Disorders. Neurochem Res
- 6.Dotania et al. (2021). A comparative account of nesfatin-1 in vertebrates. Gen Comp Endocrinol
- 7.Damian-Buda et al. (2024). Nesfatin-1: A Novel Diagnostic and Prognostic Biomarker in Digestive Diseases. Biomedicines
- 8.Wang et al. (2016). Nesfatin-1 promotes brown adipocyte phenotype. Sci Rep
- 9.UniProt — NUCB2, Nucleobindin-2 (contains Nesfatin-1), human (P80303)
- 10.Wikipedia — Nesfatin-1